The goal of this translational project is to optimize targeted T-cells with chimeric antigen receptors (CARs) for use in mesothelioma. CARs are now beginning to show activity in a number of pilot clinical trials, however two issues have emerged that provide a barrier to rapid progress in the field: 1) available preclinical models have not accurately predicted the safety of CARs, and unexpected toxicities from cytokine release and tissue damage has been reported in recent trials;2) high costs and long lead times required for vector production have slowed the clinical application of T cells expressing CARs, and prevent a facile and iterative approach to optimize CAR design and determine the optimal target structures on tumor cells. Our preliminary data establishes that T lymphocytes can be efficiently modified by mRNA electroporation without integration-associated safety concerns, and that repeated infusions of """"""""RNA CAR"""""""" T cells mediate robust antitumor effects in preclinical humanized models with disseminated tumor xenografts. Thus, this new platform affords the possibility of rapidly testing potent RNA CARs for antitumor activity, and in the event of toxicity, limiting off-target exposure by discontinuing CAR administration. Because late relapses due to tumor escape variants in pre-clinical models have been identified, it will be important to test combinations of CAR T cells to augment antitumor effects and prevent recurrence.
The specific aims are to 1) Develop a new platform technology using RNA engineering to create """"""""RNA CARs"""""""", 2) Conduct experiments using patient material from Project 1 to assess the effects of """"""""third generation"""""""" CARs, and 3) Test the anti-tumor activity of a combinatorial CAR-based immunotherapy using CARs specific for mesothelin, high molecular weight melanoma-associated (HMW-MAA) and c-Met for mesothelioma. These studies will test the central hypothesis that multiple CARs (i.e., a """"""""CAR fleet"""""""") will improve CAR immunotherapy compared to therapy with """"""""monoclonal"""""""" CARs. Furthermore, these studies will establish the safety and feasibility of increasing the therapeutic index of T cells engineered to express powerful activation domains without the associated safety concerns of integrating viral vectors.
Malignant mesothelioma is increasing in prevalence and is currently considered incurable. This project is testing methods to modify lymphocytes so that they can kill tumors efficiently, safely, and specifically. The approach includes providing lymphocytes for a clinical trial, analyzing the trial and conducting new animal experiments to widen the number of targets attacked.
|Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47|
|Sterman, Daniel H; Alley, Evan; Stevenson, James P et al. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNÎ± Combined with Chemotherapy. Clin Cancer Res 22:3791-800|
|O'Hara, Mark; Stashwick, Caitlin; Haas, Andrew R et al. (2016) Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8:449-60|
|Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90|
|Liu, X; Barrett, D M; Jiang, S et al. (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430|
|Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51|
|Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi et al. (2015) Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res 3:815-26|
|Frigault, Matthew J; Lee, Jihyun; Basil, Maria Ciocca et al. (2015) Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3:356-67|
|Lo, Albert; Wang, Liang-Chuan S; Scholler, John et al. (2015) Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res 75:2800-10|
|Liu, Xiaojun; Jiang, Shuguang; Fang, Chongyun et al. (2015) Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res 75:3596-607|
Showing the most recent 10 out of 82 publications